Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

Sponsor
Maisonneuve-Rosemont Hospital
Study ID
NCT00807196
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

  • Non-Hodgkins Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    250mg/m2 day -21 and day -14 of preparative regimen
  • 90Y ibritumomab tiuxetan (Zevalin) — DRUG
    0.4 mCi/kg IV on day -14 of preparative regimen
  • Cyclophosphamide — DRUG
    300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
  • Fludarabine — DRUG
    30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
  • Non myeloablative allogeneic stem cell transplantation — OTHER
    Blood stem cell infusion on day 0

Study Details

The purpose of this study is to investigate the ability to combine a radioactive medication directly targeted against lymphoma cells with the immune effects of an allogeneic blood stem cell transplant.

Key Dates

Start date
Sep 30, 2008
Status verified
Dec 2008
Primary completion
Dec 31, 2011
Completion
Dec 31, 2012

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: T

Primary Outcome Measure

Engraftment, chimerism, transplant related toxicity, acute and chronic GVHD [ Time Frame: one year ]

Central Contacts

Related Studies